Ines Monge-Escartin
Overview
Explore the profile of Ines Monge-Escartin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
38
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albanell-Fernandez M, Rodriguez Mues M, Figueras C, Altamirano M, Monge-Escartin I, Riu-Viladoms G, et al.
Support Care Cancer
. 2025 Mar;
33(4):261.
PMID: 40064679
Purpose: Sex influences chemotherapy-induced nausea and vomiting (CINV). However, in clinical practice, males and females receive the same antiemetic prophylaxis. We compared CINV between sexes in patients with different emetic...
2.
Escribano-Serrat S, Pedraza A, Suarez-Lledo M, Charry P, De Moner B, Martinez-Sanchez J, et al.
Bone Marrow Transplant
. 2024 Aug;
59(10):1466-1476.
PMID: 39117736
Since 2021 the use of G-CSF was implemented in allo-HCT with PTCY-based prophylaxis with the aim of shortening the aplastic phase and reducing infectious complications. This study investigates the effectiveness...
3.
Cordoba Sanchez J, Monge-Escartin I, Gil J, Carrera C, Saez-Penataro J, Ferrer L, et al.
Prostate
. 2024 Jun;
84(13):1198-1208.
PMID: 38888199
Objective: To analyse the adverse events (AEs) associated with apalutamide and the impact of a multidisciplinary team (MDT) protocol on its management at a tertiary care hospital in a real-world...
4.
Marco D, Molina M, Guio A, Julian J, Fortuna V, Fabregat-Zaragoza V, et al.
Pharmaceuticals (Basel)
. 2024 May;
17(5).
PMID: 38794124
Tacrolimus (Tac) is pivotal in preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). It has been reported that genetic factors, including * and 22 polymorphisms, have...
5.
Ruiz-Boy S, Pedraza A, Prat M, Salas M, Carcelero E, Riu-Viladoms G, et al.
Pharmaceuticals (Basel)
. 2023 Dec;
16(12).
PMID: 38139867
Cytomegalovirus (CMV) infection is a relevant cause of morbimortality in patients receiving allogeneic stem cell transplantation (allo-HCT). Foscarnet (FCN) is an effective drug against CMV administered intravenously and usually on...
6.
Albanell-Fernandez M, Perez Sanchez A, Monge-Escartin I, Riu-Viladoms G, Rodriguez Mues M, Corominas Bosch M, et al.
J Oncol Pharm Pract
. 2023 Aug;
30(6):999-1009.
PMID: 37563932
Introduction: Chemotherapy-induced nausea and vomiting (CINV) is one of the adverse events that most affects oncologic patients' quality of life. Carboplatin AUC ≥ 4 belongs to agents with high emetic...
7.
Albanell-Fernandez M, Monge-Escartin I, Cid J
Med Clin (Barc)
. 2023 Jun;
161(6):267-268.
PMID: 37385936
No abstract available.
8.
Albanell-Fernandez M, Monge-Escartin I, Carcelero-San Martin E, Riu Viladoms G, Ruiz-Boy S, Lozano M, et al.
Transfus Apher Sci
. 2023 May;
62(3):103722.
PMID: 37169697
Purpose: Caplacizumab was licensed for acquired thrombotic thrombocytopenic purpura (aTTP) based on prospective controlled trials. Real-world evidence is crucial in rare diseases. We aim to describe a patient population with...
9.
Gonzalez-Colominas E, Lopez-Mula C, Martinez-Casanova J, Luque S, Conde-Estevez D, Monge-Escartin I, et al.
Eur J Hosp Pharm
. 2022 Jan;
30(6):333-339.
PMID: 35086803
Objective: Our objective was to evaluate the prevalence of discrepancies between primary care electronic medication records (EMR) and patient reported medication (PRM) in ambulatory patients starting a hospital dispensing treatment...
10.
Conde-Estevez D, Monge-Escartin I, Rios-Hoyo A, Monzonis X, Echeverria-Esnal D, Moliner L, et al.
J Chemother
. 2020 Dec;
33(1):32-39.
PMID: 33267748
Our aim was to describe the incidence and characteristics of immune-related adverse events (irAEs) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and to evaluate...